Oft, Martin
Synthekine,
United States
2024 Rank: 100556
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 3312 out of 334837 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 100556 | 118109 |
| Total Cites | 328 | 335 |
| H-index | 10 | 10 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 35 | 35 |
| Number of Single+First Authored Papers | 6 | 6 |
| Total Cites to Single+First Authored Papers | 56 | 57 |
| Number of Single+First+Last Authored Papers | 19 | 19 |
| Total Cites to Single+First+Last Authored Papers | 213 | 215 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 262 | 264 |
| Ratio of Total Citations to Distinct Citing Papers | 1.25 | 1.27 |
| Self-Citation Percentage |
2.09%
|
|
Oft, Martin
Synthekine,
United States
2023 Rank: 83082
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 3002 out of 312644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 83082 | 97566 |
| Total Cites | 327 | 329 |
| H-index | 12 | 12 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 41 | 41 |
| Number of Single+First Authored Papers | 6 | 6 |
| Total Cites to Single+First Authored Papers | 70 | 70 |
| Number of Single+First+Last Authored Papers | 19 | 19 |
| Total Cites to Single+First+Last Authored Papers | 206 | 206 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 259 | 261 |
| Ratio of Total Citations to Distinct Citing Papers | 1.26 | 1.26 |
| Self-Citation Percentage |
0.61%
|
|
Oft, Martin
Synthekine Inc.,
United States
2022 Rank: 59932
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 2276 out of 293195 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 59932 | 69211 |
| Total Cites | 423 | 436 |
| H-index | 11 | 11 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 41 | 42 |
| Number of Single+First Authored Papers | 6 | 6 |
| Total Cites to Single+First Authored Papers | 79 | 81 |
| Number of Single+First+Last Authored Papers | 19 | 19 |
| Total Cites to Single+First+Last Authored Papers | 274 | 279 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 302 | 308 |
| Ratio of Total Citations to Distinct Citing Papers | 1.40 | 1.42 |
| Self-Citation Percentage |
2.98%
|
|
Oft, Martin
Eli Lilly and Company,
United States
2021 Rank: 71411
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1615 out of 127911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 71411 | 83209 |
| Total Cites | 517 | 527 |
| H-index | 13 | 13 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 53 | 54 |
| Number of Single+First Authored Papers | 6 | 6 |
| Total Cites to Single+First Authored Papers | 100 | 102 |
| Number of Single+First+Last Authored Papers | 18 | 18 |
| Total Cites to Single+First+Last Authored Papers | 342 | 346 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 396 | 401 |
| Ratio of Total Citations to Distinct Citing Papers | 1.31 | 1.31 |
| Self-Citation Percentage |
1.90%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.